Peptide Blends · Exact presentation
BPC-157 + TB-500 · 10 mg Blend
BPC-157 + TB-500 · 10 mg Blend is a declared multi-component single-vial blend. Evidence for each component does not automatically establish the performance of the combination.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 10 mg presentation, the reference concentration of 3.33 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 3.33 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0333 mg at this concentration.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
The source chart summarizes “600 mcg–800 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Reconstitution Steps
For a 10 mg presentation, the reference concentration of 3.33 mg/mL mathematically corresponds to 3.003 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 3.33 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.0333 mg at this concentration.
Advanced / Aggressive Approach (Acute Injury Support)
The source chart summarizes “600 mcg–800 mcg” at “Daily” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Advanced / Aggressive Approach (Acute Injury Support)
| Phase / Week | Daily Dose (Total Blend) | Each Peptide (mcg) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1000 mcg | 500 mcg BPC + 500 mcg TB-500 | 30 units (0.30 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 24 units (0.24 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 18 units (0.18 mL) |
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
The proposed mechanism depends on the molecular identity and receptor systems described in the literature. A mechanism alone does not establish clinical efficacy.
Potential Benefits & Side Effects
Identity, purity, sterility, stability, and equivalence to studied products cannot be assumed. Adverse effects and interactions may be incompletely characterized.
Source trail
Scientific references and source discovery
- PeptideDosages — exact BPC-157 + TB-500 · 10 mg Blend entrysecondary-structure
- PubMed — literature search for BPC-157 + TB-500primary-discovery
- ClinicalTrials.gov — study search for BPC-157 + TB-500trial-registry
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference